Aspirin once vs. twice daily for high-risk MPN patients
Part of Blood & lymphatic clinical trials.
This trial tests whether taking aspirin once or twice daily better prevents blood clots in high-risk patients with myeloproliferative neoplasms (MPNs) who don't respond fully to aspirin. It's for people whose blood tests show aspirin resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older with a myeloproliferative neoplasm (MPN) not linked to the Philadelphia chromosome
- Have lab-confirmed aspirin resistance (your blood doesn't respond normally to aspirin when tested in a lab)
- Not be taking blood thinners like warfarin or apixaban
- Not have active bleeding, a stomach ulcer, or a planned surgery with bleeding risk
- Have a platelet count above 50,000 per microliter of blood
- Not have another active cancer or have been cancer-free for at least 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
This trial is testing whether aspirin or a blood thinner called rivaroxaban can best prevent harmful blood clots in people newly diagnosed with multiple myeloma who have a high risk of developing clots. It aims to find a safer and more effective way to protect you during treatment.
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
This early-stage study tests how a daily aspirin tablet behaves in the body and how it affects blood/clotting markers in people with type 2 diabetes. It may help researchers understand whether this form of aspirin could be useful, especially if you’re not currently taking aspirin.
This trial tests if taking aspirin along with a standard blood thinner helps people with a HeartMate3 heart pump have fewer bleeding or clotting problems. It is for people who have had their pump for at least 3 months.
This study looks at heart and blood vessel problems in people with certain blood cancers called MPNs (myeloproliferative neoplasms). It aims to understand how these conditions affect the heart so doctors can better care for patients.
Hear when a new Myeloproliferative Neoplasms (MPN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.